Tarsus Pharmaceuticals (TARS) Enterprise Value (2019 - 2026)

Tarsus Pharmaceuticals' Enterprise Value history runs 8 years deep, the most recent figure standing at -$102.2 million for Q1 2026.

• In Q1 2026, Enterprise Value rose 74.95% year-over-year to -$102.2 million; the TTM figure through Mar 2026 stood at -$102.2 million (up 74.95% YoY), while the FY2025 annual figure was -$417.3 million, down 340.07% from the prior year.
• Enterprise Value was -$102.2 million for Q1 2026 at Tarsus Pharmaceuticals, up from -$417.3 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$94.8 million in Q4 2024 to a low of -$417.3 million in Q4 2025.
• Historically, Enterprise Value has averaged -$262.5 million across 5 years, with a median of -$245.4 million in 2022.
• The sharpest annual moves came in 2025 and 2026: Enterprise Value tumbled 340.07% in 2025, then soared 74.95% in 2026.
• A 5-year view of Enterprise Value shows it stood at -$217.0 million in 2022, then declined by 4.8% to -$227.4 million in 2023, then jumped by 58.31% to -$94.8 million in 2024, then tumbled by 340.07% to -$417.3 million in 2025, then soared by 75.51% to -$102.2 million in 2026.
• The last three Enterprise Value figures came in at -$102.2 million (Q1 2026), -$417.3 million (Q4 2025), and -$401.8 million (Q3 2025), per Business Quant data.